Goldman Sachs Maintains Revance Therapeutics Buy Recommendation

Fintel reports that on September 21, 2023, Goldman Sachs maintained coverage of Revance Therapeutics (NASDAQ:RVNC) with a Buy recommendation. As of August 31, 2023, the average one-year price target for Revance Therapeutics is 40.06. The forecasts range from a low of 20.20 to a high of $68.25. The…#goldmansachs #revancetherapeutics #worldfund #paloaltoinvestors #jpmorganchase #polarcapitalholdings #injection #revance #fda #mylannv

Source: Reuters: Health - September 22, 2023 Category: Consumer Health News Source Type: news